- Findings introduced on the annual Fall Clinical Dermatology Conference
- Survey discovered that path to analysis for folks with seborrheic dermatitis (common of three.6 years) considerably longer than estimated by physicians (common of 1.5 years)
- Prior to analysis, 71% of people with seborrheic dermatitis mentioned they’d not heard of the illness and 56% discovered it arduous to seek out info on-line
- Nearly 9 in 10 people with seborrheic dermatitis wished they’d recognized that there have been particular signs to determine seborrheic dermatitis
WESTLAKE VILLAGE, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage industrial firm centered on creating significant improvements in immuno-dermatology, at present introduced outcomes of a nationwide survey of adults with seborrheic dermatitis and the healthcare suppliers who deal with them that highlights the lengthy path to analysis and the overall ignorance and training concerning the illness. The outcomes have been introduced as a poster on the 2022 Fall Clinical Dermatology Conference in Las Vegas, Nevada. The on-line survey was performed by The Harris Poll on behalf of Arcutis and included 300 U.S. adults (18+ years of age) who had been identified with seborrheic dermatitis by a healthcare supplier, of which 84% reported their present situation to be average or extreme, and 601 licensed U.S. healthcare suppliers specializing in dermatology, together with dermatologists, nurse practitioners (NPs), and doctor assistants (PAs).
The survey discovered that people with seborrheic dermatitis usually skilled an extended and burdensome path to analysis, reporting a mean of three.6 years from symptom onset to in search of care, though sufferers reporting extreme illness sought care inside 1 yr of symptom onset. In distinction, healthcare suppliers underestimated the time it takes for folks with seborrheic dermatitis to obtain a analysis, reporting a mean of simply 1.5 years. These findings recommend that people delay in search of care regardless of experiencing signs. In addition, previous to analysis, 63% of people didn’t assume their signs have been extreme sufficient to warrant medical consideration.
“It’s staggering to see that there is a two-year difference in what healthcare professionals believe the path to diagnosis is, compared to the lengthy and frustrating journey that individuals with seborrheic dermatitis actually experience,” mentioned Raj Chovatiya, M.D., Ph.D., Assistant Professor of Dermatology and Director of the Center for Eczema and Itch on the Northwestern University Feinberg School of Medicine. “As clinicians, it’s important for us to recognize that the patient journey often starts long before the decision to seek care, as individuals often do not fully understand the scope and severity of their disease.”
According to the survey, people with seborrheic dermatitis lacked consciousness and training concerning the illness previous to analysis. Specifically, 71% mentioned that they’d not heard of seborrheic dermatitis and 56% discovered it arduous to seek out info on-line concerning the illness. In addition, most (83%) people didn’t understand all their signs (e.g., itching, flaking, redness on the face, physique, scalp and so forth.) have been because of seborrheic dermatitis, and 76% mistook their signs for one more pores and skin situation. Almost all (90%) people wished they’d recognized that there have been particular signs to determine seborrheic dermatitis. Additionally, many people with seborrheic dermatitis reported that they have been embarrassed to speak to household or pals (59%) and healthcare suppliers (58%) about signs.
“The social stigma behind skin conditions that cause visible symptoms like flaking and redness can create real and perceived barriers to diagnosis and care,” mentioned Frank Watanabe, President and Chief Executive Officer, Arcutis. “By providing more education and resources, we can help address the stigma and embarrassment that are often associated with seborrheic dermatitis, help reduce the time from symptom onset to diagnosis, and ultimately help to improve the care of those living with the condition.”
Seborrheic dermatitis impacts greater than 10 million folks within the U.S., and is a typical, power or recurrent inflammatory pores and skin illness that causes purple patches coated with massive, greasy, flaking yellow-gray scales, and protracted itch.
Arcutis beforehand reported topline survey ends in May 2022, and anticipate future information analyses to proceed all through 2023.
A Media Snippet accompanying this announcement is obtainable by clicking on the picture or hyperlink beneath:
About the Survey
The affected person survey was performed on-line by The Harris Poll on behalf of Arcutis Biotherapeutics amongst 300 U.S. adults 18+ years of age who’ve been identified with seborrheic dermatitis by a healthcare supplier (together with an oversample to succeed in 60 who’re Black/African American). The survey was performed December 14, 2021 by way of January 19, 2022. Figures for age, intercourse, training, race/ethnicity, area, revenue, family dimension, and marital standing have been weighted the place essential to convey the info into line with precise proportions within the inhabitants. Black/African American sufferers have been balanced again to pure fall out among the many certified sufferers. A propensity rating variable was additionally included to regulate for respondents’ propensity to be on-line.
The HCP survey was performed on-line by The Harris Poll on behalf of Arcutis Biotherapeutics amongst 601 HCPs (together with dermatologists, NPs, and PAs) specializing in dermatology who see not less than 1 affected person per week and frequently see 1+ sufferers with seborrheic dermatitis per yr. The survey was performed December 16, 2021 by way of January 19, 2022. For Dermatologists, figures for years in observe, gender, and area have been weighted the place essential to convey the info into line with precise proportions within the inhabitants. For NP/PAs, uncooked information weren’t weighted and are subsequently solely consultant of the people who accomplished the survey.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology firm that champions significant innovation to deal with the pressing wants of sufferers dwelling with immune-mediated dermatological illnesses and situations. With a dedication to fixing essentially the most persistent affected person challenges in dermatology, Arcutis harnesses our distinctive dermatology improvement platform coupled with our dermatology experience to construct differentiated therapies towards biologically validated targets. Arcutis’ dermatology improvement platform features a strong pipeline with a number of scientific applications for a variety of inflammatory dermatological situations together with scalp and physique psoriasis, atopic dermatitis, and seborrheic dermatitis. For extra info, go to www.arcutis.com or comply with Arcutis on LinkedIn, Facebook, and Twitter.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
[email protected]
Investors
Eric McIntyre, Head of Investor Relations
[email protected]
